Page 115

Marzo_2017

385 Documento Declaración de la Academia Chilena de Medicina del Instituto de Chile sobre ensayos clínicos - G. López et al lenos con tirosinemia tipo I tratados con 2-(2-nitro-4- trifluorometilbenzoil)- 1,3-ciclohexanediona (NTBC). Rev Med Chile 2012; 140: 169-75. 8. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere E, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008; 31: 81-7. 9. Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2006; 2: 365-75. 10. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806. 11. Kappos L, Radue E-M, O’Connor P. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355:1124-40. ClinicalTrials.gov NCT00333138 core study y NCT00235430 extension. 12. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A Randomized, Placebo Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N Engl J Med 2006; 354: 899-910. 13. Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Muñoz ET, et al. Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011; 118: 5767-73. 14. Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 2012; 36: 543-53. 15. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med 2007; 146: 77-86. 16. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322- 9. 17. Galie N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB, et al. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Lancet 2008; 371: 2093-100. ClinicalTrials.gov NCT00091715. 18. Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C. Treatment of patients with mildly symptomatic  pulmonary  arterial  hypertension  with bosentan (EARLY study): a double-blind, randomised controlled trial. Am J Cardiol 2011; 108: 302-7. 19. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102: 531-7. 20. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-83. 21. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Current management. Journal of Crohn’s and Colitis 2010; 4: 28-62. 22. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years. Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002; 25: 593-8.  23. Sofaer N. Reciprocity-based reasons for benefiting research participants: Most fail, the most plausible is problematic. Bioethics 2014; 28: 456-71. 24. Mieres C. Las grietas de la Ley Ricarte Soto. Portafolio Salud Junio 2015; 30-5. 25. WHO International Clinical Trials Registry Platform (ICTRP). Disponible en www.who.int/ictrp/network/ primary/en/index.html Rev Med Chile 2017; 145: 380-385


Marzo_2017
To see the actual publication please follow the link above